Want to know how healthy your heart is? Now there's an app for that.
In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health. What used to require a 45-minute scan from an ultrasound machine can now be accomplished by simply holding your phone up to your neck for a minute or two.
The team developed a technique that can infer the left ventricular ejection fraction (LVEF) of the heart by measuring the amount that the carotid artery displaces the skin of the neck as blood pumps through it. LVEF represents the amount of blood in the heart that is pumped out with each beat. In a normal heart, this LVEF ranges from 50 to 70 percent. When the heart is weaker, less of the total amount of blood in the heart is pumped out with each beat, and the LVEF value is lower.
LVEF is a key measure of heart health, one upon which physicians base diagnostic and therapeutic decisions.
"In a surprisingly short period of time, we were able to move from invention to the collection of validating clinical data," says Caltech's Mory Gharib (PhD '83), senior author of a paper on the study that was published in the July issue of the Journal of Critical Care Medicine. Gharib is the Hans W. Liepmann Professor of Aeronautics and Bioinspired Engineering.
Three of the co-authors of the study, Derek Rinderknecht (PhD '08), Niema Pahlevan (PhD '13), and Peyman Tavallali (PhD '14), developed this technology as students or research engineers at Caltech. They have since teamed up with former Caltech visitor in medical engineering Marianne Razavi, another author of the study, to found a start-up named Avicena that has licensed this technology and will market the app. Gharib is an unpaid board member of Avicena and Pahlevan is currently an assistant professor at USC.
To test the app, clinical trials were conducted with 72 volunteers between the ages of 20 and 92 at an outpatient magnetic resonance imaging (MRI) facility. MRI is the gold standard in measuring LVEF but is seldom used clinically due to its high cost and limited availability. LVEF is most commonly measured using an ultrasound machine during a procedure known as echocardiography. Echocardiography, however, requires a trained technician, an expensive ultrasound machine, and up to 45 minutes of a patient's time.
To measure LVEF using the technique developed at Caltech, doctors simply held iPhones against the volunteers' necks for one to two minutes. Afterwards, the volunteers immediately received an MRI examination, and data from both tests were compared. The measurements made by smartphone had a margin of error of ± 19.1 percent compared with those done in an MRI. By way of comparison, the margin of error for echocardiography is around ± 20.0 percent. (That means, for example, if the app generated an LVEF reading of 40, it would have a margin of error of 40 x 19 percent, which equals about plus or minus 7.6 points.)
"What is exciting about this study is that it shows our technique is as accurate as echocardiography at estimating LVEF when both are compared to the gold standard of cardiac MRI. This has the potential to revolutionize how doctors and patients can screen for and monitor heart disease both in the U.S. and the developing world," Gharib says.
The app works because the walls of arteries are almost completely elastic--they expand and contract with each beat of the heart. That expanding and contracting can be measured and described as a waveform that encodes information about the heart. For the study, the team used an iPhone 5, but any smartphone with a camera will work.
Gharib and his team are exploring what other information about the heart can be mined from the waveform captured by the app. Soon, he anticipates that the technique could be used to diagnose heart valve diseases, like aortic stenosis, and coronary artery blockages.
Other co-authors include Marie Csete (MS '98, PhD '00) and Thao Tran of Huntington Medical Research Institutes; and Michael Fong and Robert Kloner of the Keck School of Medicine of USC.
This research was supported by the Rothenberg Innovation Initiative (RI2) program.